Did Eliezer Masliah Cheat?

Eliezer Masliah学术术欺诈？

Decades of Doubt in Alzheimer's and Parkinson's Research

阿尔茨海默氏症和帕金森氏症研究数十年来的疑云

The Researcher Daily，Sep 27

研究者日报，9月27日

逃离科研-九九年的老人

Did you know, the scientific community is currently facing some serious turmoil with allegations against Eliezer Masliah, a well-known neuroscientist at the National Institute on Aging. Masliah has been a big name in researching neurodegenerative diseases like Alzheimer's and Parkinson's, and his work has had a major impact. But now, we’re hearing troubling reports about potential misconduct in his research, specifically around claims of image manipulation in important studies.

你知道吗，因为美国国家老龄化研究所（National Institute on Aging）的著名神经科学家埃利泽-马斯利亚

（Eliezer Masliah）受到了学术不端的指控，科学界沸腾了。马斯利亚在阿尔茨海默氏症和帕金森氏症等神经

退化疾病的研究领域是个响亮的名字，他的工作在科学界已经产生了重大影响。但现在有麻烦了，因为Eliezer Masliah的研究很可能是学术不端的结果，在一些重要研究中被指控图表造假。

Eliezer Masliah, MD Director, Division of Neuroscience, National Institute on Aging

Eliezer Masliah，医学博士， 国家老龄问题研究所神经科学部主任

Just last year, forensic analysts raised red flags about Masliah’s papers on PubPeer, leading to a thorough review by researchers, including folks from Columbia University. They found multiple instances of duplicated and altered images in various publications. This prompted Science¹ and the NIH to step in and investigate, and it’s all tied to ongoing clinical trials, including one for a drug called prasinezumab.

就在去年，分析师在 PubPeer 上对马斯利亚发表的论文提出了质疑，包括哥伦比亚大学在内的研究人员正在进行了彻底审查。他们在马斯利亚的文章中发现了大量重复使用和篡改图片。Science 期刊和美国国立卫生研究院（NIH）不得不介入调查，而这一切都与正在进行的临床试验有关，其中包括一种名为普拉嗪单抗（prasinezumab）的药物。

Prasinezumab² has been developed to help combat the spread of toxic alpha-synuclein in Parkinson's disease, and there’s been a lot of hope surrounding it. But with these allegations stacking up against Masliah, questions are surfacing about the foundational studies that back this drug. Some critical papers cited in its development are now under scrutiny for containing manipulated images. For example, a 2015 study suggested that Cerebrolysin could reduce tau damage, but the images presented look suspiciously similar to one another. That’s a huge concern for the reliability of the data.

Prasinezumab²的开发是为了帮助对抗帕金森病中有毒的α-突触核蛋白的扩散，人们对它充满了希望。

但是，因为对马斯利亚的大量指控控，支撑这种药物的基础成为问题。

该药物研发过程中依据的关键论文因含有被篡改的图像而受到审查。

例如，2015 年的一项研究表明，脑复康可以减少 tau 损伤，但所展示的图片互相十分相似。

这让人非常怀疑数据的可靠性。

====

大咖们写的综述有多大的学术价值？

科学研究可以是不科学的

文章质量可以用影响因子评估吗 

高被引的文章并不代表是好文章 

排行凸显的高他引论文鲜有原创 

颠覆性成果很难发表在顶刊 

垃圾文章的大量产出导致的问题不仅仅是虚假繁荣 

为什么当代出版实践扭曲了科学 

逃离科研-九九年的老人

北大教授乔晓春：高被引论文并不代表高质量论文

上海交通大学杨枫教授-把学术界改造成美丽世界

=======

This isn’t just about one researcher, though. The implications here are massive. If the research that supports neurodegenerative disease therapies like prasinezumab is flawed, we could be looking at a major setback in drug development. George Perry, who edits the Journal of Alzheimer’s Disease, put it well when he said that

不过，这不仅仅是一个研究人员的问题。它的影响是巨大的。如果支持神经退行性疾病疗法

（如 prasinezumab）的研究存在问题，那么药物开发可能存在重大问题。关于这个问题，《阿尔茨海默病杂志》的编辑

乔治-佩里（George Perry）说得很好。

Adding to the complexity, the NIH hasn't regularly reviewed researchers’ past work before hiring them, which raises serious questions about the vetting process. Critics argue that we need proactive screening to maintain research integrity, especially in fields where lives are on the line.

更为复杂的是，美国国立卫生研究院授予研究人员项目经费后并没有定期审查他们的工作，

这就对审查过程是否可靠提出了严重的质疑。批评者认为，对于学术诚信我们需要更加主动，以保持研究的完整性，尤其是在人命关天的领域。

Reactions to these allegations have been mixed. Some people are cautious about blaming Masliah’s collaborators, many of whom might not have been aware of any wrongdoing. But others feel that those close to him should have noticed the patterns of manipulation over the years. This situation really highlights the challenges of accountability in scientific research, especially in collaborative environments.

人们对这些指控的反应是复杂的。

一些人以并不认为与马斯利亚的合作项目存在学术诚信问题，他们支持马斯利亚。

另一些人认为，与他关系密切的人需要注意到多年来马斯利亚的文章一直存在图片操纵。

这种情况确实凸显了科学研究中科学家的诚信问题，尤其是在合作研究的环境中。

==============

面对利益和真理，主流科学家更珍视前者

对于大多数主流权威犯的浅显而严重的错误视而不见是现代科学界的一个严重问题

明知是错误的文章，仍然坚持发表，是恶劣的学术不端

科学界是一个保守的体系，科学家并不愿意接受新思想

科学就是质疑；你好，我好，大家都好就不会有科学 

https://www.peeref.com/roulette-hubs/1044

“A considerable number of individuals are inclined to align with authority, 

seemingly believing that this aligning somehow validates their own greatness. ”

http://www.staradvertiser.com/2018/10/16/news/harvard-calls-for-retraction-of-dozens-of-studies-by-noted-cardiologist/

16 Oct 2018

Harvard calls for retraction of dozens of studies by noted cardiologist, New York Times .

“some scientists wondered how a questionable line of research persisted for so long … 

experts were just too timid to take a stand.”

=====

转载本文请联系原作者获取授权，同时请注明本文来自刘跃科学网博客。

链接地址：https://wap.sciencenet.cn/blog-3589443-1453047.html?mobile=1

收藏

分享